Pathophysiology and biomarkers of acute respiratory distress syndrome

被引：71

作者：

Fujishima S. ^{[1
]}

机构：

[1] Center for General Internal Medicine and Education, School of Medicine, Keio University, Tokyo

来源：

Journal of Intensive Care | / 2卷 / 1期

基金：

日本学术振兴会;

关键词：

Berlin definition; Cytokine; Damage-associated molecular patterns; IL-18; IL-8; Leptin;

D O I：

10.1186/2052-0492-2-32

中图分类号：

学科分类号：

摘要：

Acute respiratory distress syndrome (ARDS) is defined as an acute-onset, progressive, hypoxic condition with radiographic bilateral lung infiltration, which develops after several diseases or injuries, and is not derived from hydrostatic pulmonary edema. One specific pathological finding of ARDS is diffuse alveolar damage. In 2012, in an effort to increase diagnostic specificity, a revised definition of ARDS was published in JAMA. However, no new parameters or biomarkers were adopted by the revised definition. Discriminating between ARDS and other similar diseases is critically important; however, only a few biomarkers are currently available for diagnostic purposes. Furthermore, predicting the severity, response to therapy, or outcome of the illness is also important for developing treatment strategies for each patient. However, the PaO2/FIO2 ratio is currently the sole clinical parameter used for this purpose. In parallel with progress in understanding the pathophysiology of ARDS, various humoral factors induced by inflammation and molecules derived from activated cells or injured tissues have been shown as potential biomarkers that may be applied in clinical practice. In this review, the current understanding of the basic pathophysiology of ARDS and associated candidate biomarkers will be discussed. © 2014 Fujishima.

引用

共 43 条

[11]

Martinez-Gonzalez I., Roca O., Masclans J.R., Moreno R., Salcedo M.T., Baekelandt V., Cruz M.J., Rello J., Aran J.M., Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury, Am J Respir Cell Mol Biol, 49, 4, pp. 552-562, (2013)

[12]

Dolinay T., Kim Y.S., Howrylak J., Hunninghake G.M., An C.H., Fredenburgh L., Massaro A.F., Rogers A., Gazourian L., Nakahira K., Haspel J.A., Landazury R., Eppanapally S., Christie J.D., Meyer N.J., Ware L.B., Christiani D.C., Ryter S.W., Baron R.M., Choi A.M., Inflammasome-regulated cytokines are critical mediators of acute lung injury, Am J Respir Crit Care Med, 185, 11, pp. 1225-1234, (2012)

[13]

Opitz B., Van Laak V., Eitel J., Suttorp N., Innate immune recognition in infectious and noninfectious diseases of the lung, Am J Respir Crit Care Med, 181, 12, pp. 1294-1309, (2010)

[14]

Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J., HMG-1 as a late mediator of endotoxin lethality in mice, Science, 285, 5425, pp. 248-251, (1999)

[15]

Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Maeda S., Yamagishi S., Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome, Clin Biochem, 44, 8-9, pp. 601-604, (2011)

[16]

Ueno H., Matsuda T., Hashimoto S., Amaya F., Kitamura Y., Tanaka M., Kobayashi A., Maruyama I., Yamada S., Hasegawa N., Soejima J., Koh H., Ishizaka A., Contributions of high mobility group box protein in experimental and clinical acute lung injury, Am J Respir Crit Care Med, 170, 12, pp. 1310-1316, (2004)

[17]

Abrams S.T., Zhang N., Manson J., Liu T., Dart C., Baluwa F., Wang S.S., Brohi K., Kipar A., Yu W., Wang G., Toh C.H., Circulating histones are mediators of trauma-associated lung injury, Am J Respir Crit Care Med, 187, 2, pp. 160-169, (2013)

[18]

Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., Brohi K., Itagaki K., Hauser C.J., Circulating mitochondrial DAMPs cause inflammatory responses to injury, Nature, 464, 7285, pp. 104-107, (2010)

[19]

Levitt J.E., Vinayak A.G., Gehlbach B.K., Pohlman A., Van Cleve W., Hall J.B., Kress J.P., Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study, Crit Care, 12, 1, (2008)

[20]

Rana R., Vlahakis N.E., Daniels C.E., Jaffe A.S., Klee G.G., Hubmayr R.D., Gajic O., B-type natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema, Crit Care Med, 34, 7, pp. 1941-1946, (2006)

← 1 2 3 4 5 →